Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

Sponsor
Hellenic Oncology Research Group
Study ID
NCT02179567
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
  • Bevacizumab — DRUG
    Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks

Study Details

The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer

Key Dates

First listed
Jul 2, 2014
Start date
Mar 31, 2010
Status verified
Sep 2015
Primary completion
Mar 31, 2013
Completion
Mar 31, 2013

Study Design

Enrollment
26 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Doc/Bev
    Docetaxel/Bevacizumab

Primary Outcome Measure

Overall Response Rate [ Time Frame: Disease evaluation at Week 9 ]

Related Studies